Utilizing further RNAi-based synthetic lethal screening, we found that suppression of SCRN1 in erlotinib-resistant clones restores drug sensitivity, suggesting that upregulation of SCRN1 may be a new mechanism for rendering the EGFR mutant-lung cancer cell lines to erlotinib resistance. Here, SCRN1 is linked to lung carcinoma.